Induced pluripotent stem cells restore function in a human cell loss model of open-angle glaucoma

Stem Cells

Volumn 33, Issue 3, 2015, Pages 751-761

  Abu Hassan, Diala W ^a   Li, Xinbo ^a   Ryan, Eileen I ^a   Acott, Ted S ^a   Kelley, Mary J ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Autologous stem cell transplantation; Cell transplantation; Experimental models; Induced pluripotent stem cells; Somatic stem cells; Stem cell transplantation; Tissue regeneration; Transplantation

Indexed keywords

ALPHA3 INTEGRIN; DETERGENT; KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; SAPONIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ARTICLE; CELL ADHESION; CELL DENSITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL LOSS; CELL PHAGOCYTOSIS; CELL POPULATION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EMBRYO; EMBRYOID BODY; EXPERIMENTAL GLAUCOMA; FLOW RATE; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; NONHUMAN; OPEN ANGLE GLAUCOMA; ORGAN CULTURE; PERFUSION PRESSURE; PLURIPOTENT STEM CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE; TRABECULAR MESHWORK; UMBILICAL VEIN ENDOTHELIAL CELL; AUTOTRANSPLANTATION; CYTOLOGY; GENETICS; GLAUCOMA, OPEN-ANGLE; METABOLISM; PHYSIOLOGY; PROCEDURES; STEM CELL TRANSPLANTATION; TISSUE REGENERATION;

CELL DIFFERENTIATION; GLAUCOMA, OPEN-ANGLE; GUIDED TISSUE REGENERATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84923261289     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1885     Document Type: Article

References (51)

1. Quigley HA,. Glaucoma. Lancet 2011; 377: 1367-1377.
2. Quigley HA, Broman AT,. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267.
3. Morrison JC, Pollack IP, eds. Glaucoma: Science and Practice. New York, Stuttgart: Thieme Medical Publishers, 2003, p 34-41, p 150-162, p 354-362.
4. Acott TS, Kelley MJ, Keller KE, et al. Intraocular pressure homeostasis: Maintaining balance in a high-pressure environment. J Ocul Pharmacol Ther 2014; 30: 94-101.
5. Tamm ER,. The trabecular meshwork outflow pathways: Structural and functional aspects. Exp Eye Res 2009; 88: 648-655.
6. Overby DR, Stamer WD, Johnson M,. The changing paradigm of outflow resistance generation: Towards synergistic models of the JCT and inner wall endothelium. Exp Eye Res 2009; 88: 656-670.
7. Stamer WD, Acott TS,. Current understanding of conventional outflow dysfunction in glaucoma. Curr Opin Ophthalmol 2012; 23: 135-143.
8. Acott TS, Kelley MJ,. Extracellular matrix in the trabecular meshwork (Review). Exp Eye Res 2008; 86: 543-561.
9. Keller K, Aga M, Bradley J, et al. Extracellular matrix turnover and outflow resistance. Exp Eye Res 2009; 88: 676-682.
10. Allingham RR, Liu Y, Rhee DJ,. The genetics of primary open-angle glaucoma: A review. Exp Eye Res 2009; 88: 837-844.
11. Gemenetzi M, Yang Y, Lotery AJ,. Current concepts on primary open-angle glaucoma genetics: A contribution to disease pathophysiology and future treatment. Eye (Lond) 2012; 26: 355-369.
12. Fan BJ, Wiggs JL,. Glaucoma: Genes, phenotypes, and new directions for therapy. J Clin Invest 2010; 120: 3064-3072.
13. Ray K, Mookherjee S,. Molecular complexity of primary open angle glaucoma: Current concepts. J Genet 2009; 88: 451-467.
14. Alvarado J, Murphy C, Juster R,. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology 1984; 91: 564-579.
15. Kelley MJ, Rose AY, Keller KE, et al. Stem cells in the trabecular meshwork: Present and future promises. Exp Eye Res 2009; 88: 747-751.
16. Alvarado J, Murphy C, Polansky J, et al. Age-related changes in trabecular meshwork cellularity. Invest Ophthalmol Vis Sci 1981; 21: 714-727.
17. Grierson I, Howes RC,. Age-related depletion of the cell population in the human trabecular meshwork. Eye 1987; 1 (Pt 2): 204-210.
18. Acott TS, Samples JR, Bradley JMB, et al. Trabecular repopulation by anterior trabecular meshwork cells after laser trabeculoplasty. Am J Ophthalmol 1989; 107: 1-6.
19. Du Y, Roh DS, Mann MM, et al. Multipotent stem cells from trabecular meshwork become phagocytic TM cells. Invest Ophthalmol Vis Sci 2012; 53: 1566-1575.
20. Du Y, Yun H, Yang E, et al. Stem cells from trabecular meshwork home to TM tissue in vivo. Invest Ophthalmol Vis Sci 2013; 54: 1450-1459.
21. Okano H, Yamanaka S,. iPS cell technologies: Significance and applications to CNS regeneration and disease. Mol Brain 2014; 7: 22.
22. Takahashi K, Yamanaka S,. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
23. Yamanaka S,. Induced pluripotent stem cells: Past, present, and future. Cell Stem Cell 2012; 10: 678-684.
24. Yamanaka S,. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007; 1: 39-49.
25. Alvarado JA, Wood I, Polansky JR,. Human trabecular cells. II. Growth pattern and ultrastructural characteristics. Invest Ophthalmol Vis Sci 1982; 23: 464-478.
26. Alexander JP, Samples JR, Van Buskirk EM, et al. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci 1991; 32: 172-180.
27. Polansky JR, Weinreb R, Alvarado JA,. Studies on human trabecular cells propagated in vitro. Vision Res 1981; 21: 155-160.
28. Polansky JR, Weinreb RN, Baxter JD, et al. Human trabecular cells. I. Establishment in tissue culture and growth characteristics. Invest Ophthalmol Vis Sci 1979; 18: 1043-1049.
29. Johnson DH, Tschumper RC,. Human trabecular meshwork organ culture. Invest Ophthalmol Vis Sci 1987; 28: 945-953.
30. Johnson DH, Tschumper RC,. The effect of organ culture on human trabecular meshwork. Exp Eye Res 1989; 49: 113-127.
31. Bradley JMB, Kelley MJ, Zhu XH, et al. Effects of mechanical stretching on trabecular matrix metalloproteinases. Invest Ophthalmol Vis Sci 2001; 42: 1505-1513.
32. Bradley JMB, Vranka JA, Colvis CM, et al. Effects of matrix metalloproteinase activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci 1998; 39: 2649-2658.
33. Acott TS, Kingsley PD, Samples JR, et al. Human trabecular meshwork organ culture: Morphology and glycosaminoglycan synthesis. Invest Ophthalmol Vis Sci 1988; 29: 90-100.
34. Lu Z, Overby DR, Scott PA, et al. The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes. Exp Eye Res 2008; 86: 271-281.
35. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
36. Tomarev SI, Wistow G, Raymond V, et al. Gene expression profile of the human trabecular meshwork: NEIBank sequence tag analysis. Invest Ophthalmol Vis Sci 2003; 44: 2588-2596.
37. Stamer WD, Peppel K, O'Donnell ME, et al. Expression of aquaporin-1 in human trabecular meshwork cells: Role in resting cell volume. Invest Ophthalmol Vis Sci 2001; 42: 1803-1811.
38. Stamer WD, Snyder RW, Smith BL, et al. Localization of aquaporin CHIP in the human eye: Implications in the pathogenesis of glaucoma and other disorders of ocular fluid balance. Invest Ophthalmol Vis Sci 1994; 35: 3867-3872.
39. Liton PB, Luna C, Challa P, et al. Genome-wide expression profile of human trabecular meshwork cultured cells, nonglaucomatous and primary open angle glaucoma tissue. Mol Vis 2006; 12: 774-790.
40. Liton PB, Liu X, Stamer WD, et al. Specific targeting of gene expression to a subset of human trabecular meshwork cells using the chitinase 3-like 1 promoter. Invest Ophthalmol Vis Sci 2005; 46: 183-190.
41. Gonzalez P, Epstein DL, Borras T,. Characterization of gene expression in human trabecular meshwork using single-pass sequencing of 1060 clones. Invest Ophthalmol Vis Sci 2000; 41: 3678-3693.
42. Johnson M, Erickson K,. Mechanisms and routes of aqueous humor drainage. In:, Albert D, Jakobiec F, eds. Principles and Practice of Ophthalmology. 2nd ed. Philadelphia: W.B. Saunders, 2000: 2577-2595.
43. Johnson DH, Richardson TM, Epstein DL,. Trabecular meshwork recovery after phagocytic challenge. Curr Eye Res 1989; 8: 1121-1130.
44. Johnson M,. 'What controls aqueous humour outflow resistance?'. Exp Eye Res 2006; 82: 545-557.
45. Tsai JC,. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 2009; 116: S30-36.
46. Kholdebarin R, Campbell RJ, Jin YP, et al. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol 2008; 43: 454-461.
47. Vandenbroeck S, De Geest S, Dobbels F, et al. Prevalence and correlates of self-reported nonadherence with eye drop treatment: The Belgian Compliance Study in Ophthalmology (BCSO). J Glaucoma 2011; 20: 414-421.
48. Robin A, Grover DS,. Compliance and adherence in glaucoma management. Indian J Ophthalmol 2011; 59 suppl: S93-96.
49. Raymond V,. Molecular genetics of the glaucomas: Mapping of the first five "GLC" loci. Am J Hum Genet 1997; 60: 227-277.
50. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192.
51. Streilein JW,. Anterior chamber associated immune deviation: The privilege of immunity in the eye. Surv Ophthalmol 1990; 35: 67-73.